The newest IQVIA report reminds us of the strength of the oncology biosimilars bevacizumab, rituximab, and trastuzumab. Not only are these oncology biosimilars thriving, payers are making it increasingly difficult to obtain treatment with the innovator products when oncology biosimilars like these are available. The number of formulary exclusions nationally for all oncology products is … Continue reading IQVIA Confirms the Staying Power of Biosimilars in the Oncology Market